inConversation with Mr Harpal Singh
As pharmaceutical manufacturing transitions into a more connected and data intensive era, the integration of digital factory platforms and advanced supply chain technologies is reshaping how companies manage operations, compliance, and product traceability. What was once a largely siloed manufacturing environment is now steadily evolving into an interconnected ecosystem where equipment, enterprise systems, and regulatory frameworks converge to create a more transparent and responsive production landscape.
In this conversation, Harpal Singh reflects on the broader technological shifts influencing pharmaceutical manufacturing and supply chain management. The discussion explores the growing role of digital infrastructure in enhancing operational intelligence, strengthening regulatory alignment, and enabling end to end visibility across the pharmaceutical value chain, while also examining how serialization and interoperability are shaping the future architecture of global pharmaceutical distribution.
Pharmaceutical manufacturing plants are evolving into digitally connected production environments where equipment, software platforms, and enterprise systems generate continuous streams of operational data. From your perspective, how are digital factory platforms helping manufacturers gain deeper visibility into shop floor performance and enabling faster, more informed operational decisions?
Digital factory platforms transform pharmaceutical plants from data, generating environments into decision, driven operations. By integrating equipment data, MES, maintenance systems, and enterprise platforms, they create a real, time operational view of the shop floor.
This connectivity enables manufacturers to monitor equipment performance, batch progress, and process deviations in real time, allowing faster identification of bottlenecks or anomalies. Instead of relying on delayed reports or manual records, operational teams can make immediate, data, backed decisions that improve production continuity and quality control.
Additionally, by linking operational, maintenance, and quality data, these platforms provide contextual insights, helping manufacturers trace issues, optimize processes, and strengthen regulatory compliance.
In essence, digital factory platforms enable pharma manufacturers to move from reactive operations to proactive, data, driven manufacturing aligned with Pharma 4.0 principles.
We cannot scale the mountain in a day but taking steps towards digital transformations the key to a future which is built in data rather than ambiguity
In a GMP regulated industry, operational digitization must coexist with strict expectations around data integrity, electronic records, and audit readiness. How can pharmaceutical companies deploy digital manufacturing platforms while ensuring alignment with global regulatory frameworks and compliance standards?
In GMP, regulated environments, digital manufacturing platforms must be designed with compliance and data integrity built into the architecture, not added afterward. Pharmaceutical companies achieve this by aligning platforms with regulatory expectations such as ALCOA+ data integrity principles, 21 CFR Part 11, and EU Annex 11.
Key practices include implementing secure electronic records and signatures, role, based access control, complete audit trails, and validated system workflows. Every operational event, whether batch execution, equipment interaction, or data modification, must be time, stamped, traceable, and attributable.
Equally important is maintaining a structured validation lifecycle (CSV/CSA), ensuring the platform is tested, documented, and controlled according to GMP guidelines.
When designed this way, digital manufacturing platforms not only maintain compliance but actually strengthen audit readiness, improve traceability, and enhance regulatory confidence in digital operations.
Today with wearables and Smart technologies we can create an evidence based execution and audit matrix with a live proof of all critical operations available to the organisation with audit trail.
Once production data becomes structured and digitally accessible, the next challenge lies in extending that visibility beyond the plant. How are pharmaceutical manufacturers connecting manufacturing intelligence with broader supply chain systems to maintain continuity of information from batch production to distribution?
Once production data becomes structured and digitally accessible, pharmaceutical manufacturers extend this visibility by integrating manufacturing systems with enterprise and supply chain platforms such as ERP, warehouse management, and serialization systems.
This integration allows batch, level manufacturing data, production status, quality release information, and material traceability, to flow seamlessly from the plant floor to downstream supply chain operations. As a result, stakeholders across manufacturing, quality, logistics, and distribution operate from the same synchronized dataset.
By connecting manufacturing intelligence with supply chain systems, companies gain end,-to-end batch visibility, enabling faster product release, improved inventory planning, and stronger traceability from production through packaging, distribution, and market delivery. This continuity of information strengthens both operational efficiency and regulatory compliance across the product lifecycle.
Serialization has now become a structural requirement across many pharmaceutical markets, shaped by regulations such as the US Drug Supply Chain Security Act and the EU Falsified Medicines Directive. How have track and trace platforms evolved to help manufacturers manage the operational and regulatory complexity associated with global serialization programs?
Track, and, trace platforms have evolved from simple serialization repositories into end, to, end supply chain compliance systems. Modern platforms enable manufacturers to generate, manage, and verify unique product identifiers while maintaining full traceability of each unit across packaging, distribution, and dispensing.
To address regulatory complexity across markets such as DSCSA in the United States and the EU Falsified Medicines Directive, these systems now support multi, country compliance frameworks, integrating with packaging lines, enterprise systems, and national verification networks.
Operationally, they provide aggregation management, real, time event reporting, and product movement tracking, allowing manufacturers to monitor serialized products across the entire supply chain. This ensures regulatory reporting, improves counterfeit protection, and enables rapid product verification or recall when necessary.
In essence, modern track, and, trace platforms allow pharmaceutical companies to manage global serialization programs while maintaining regulatory compliance, supply chain transparency, and patient safety.
With the US DSCSA moving toward full supply chain interoperability, pharmaceutical companies must enable secure exchange of serialized product data across manufacturers, wholesalers, and dispensers. What technical and operational challenges are companies facing as they prepare their serialization infrastructure for large scale data exchange and verification?
As the US Drug Supply Chain Security Act (DSCSA) moves toward full interoperability, pharmaceutical companies are facing several technical and operational challenges in preparing their serialization infrastructure for large, scale data exchange.
Technically, organizations must ensure system interoperability between manufacturers, wholesalers, and dispensers, which requires standardized data formats, secure communication protocols, and integration between serialization systems, ERP platforms, and partner networks. Managing high volumes of serialized transaction data while maintaining system performance and data accuracy is also a major challenge.
Operationally, companies must establish robust verification and exception, handling processes, ensuring that serialized product information can be authenticated quickly across trading partners. This requires strong data governance, partner onboarding, and alignment on interoperability standards.
In addition to this the Issue Management poses a real challenge if there is lack of expertise in an organization and then can very quickly spiral into inventory build up.
Ultimately, the challenge lies in building a serialization ecosystem that can support secure, real, time product verification and traceability across the entire pharmaceutical supply chain, while maintaining regulatory compliance and operational efficiency.
Serialized supply chains involve multiple stakeholders including manufacturers, CMOs, wholesalers, distributors, and pharmacies. How do verification routing platforms support secure authentication of serialized medicines while maintaining interoperability and protecting sensitive commercial data across such distributed networks?
Verification Routing Services (VRS) platforms are designed to securely authenticate serialized medicines across a distributed pharmaceutical supply chain while maintaining interoperability between multiple stakeholders.
Technically, VRS platforms act as a secure query, and, response network. When a wholesaler or dispenser needs to verify a product, a request is routed through the VRS to the appropriate manufacturer’s serialization repository. The manufacturer’s system then confirms whether the serialized identifier is valid, inactive, recalled, or suspect, and returns a verification response in real time.
To maintain interoperability, these platforms use standardized data exchange protocols and network frameworks, allowing different trading partners and systems to communicate without exposing internal databases.
At the same time, VRS platforms protect sensitive commercial data by routing verification requests without sharing proprietary supply chain information, ensuring that only the minimum necessary data for authentication is exchanged.
In essence, VRS enables secure, scalable product verification across manufacturers, wholesalers, and dispensers, supporting DSCSA interoperability while safeguarding both patient safety and commercial confidentiality.
Beyond regulatory compliance, serialization infrastructure is also generating a valuable layer of supply chain intelligence. How can pharmaceutical companies use track and trace data to improve supply chain transparency, identify potential disruptions earlier, and strengthen product security across global distribution channels?
Beyond regulatory compliance, serialization systems generate granular product movement data across the entire pharmaceutical supply chain. When analyzed effectively, this data becomes a powerful source of supply chain intelligence.
First, track, and, trace data provides end, to, end product visibility, allowing manufacturers to monitor how serialized units move from packaging lines through wholesalers and distributors to final markets. This transparency helps organizations quickly identify location, ownership, and status of specific product batches at any point in the distribution network.
Second, by analyzing transaction and aggregation events, companies can detect early indicators of supply chain disruptions, such as unusual shipment delays, inventory imbalances, or abnormal product movement patterns. These insights allow manufacturers to intervene earlier and maintain supply continuity.
Finally, serialization data strengthens product security and anti, counterfeiting efforts. By validating product identities and monitoring distribution pathways, manufacturers can identify diversion, parallel trade, or suspicious product activity, helping protect both brand integrity and patient safety.
In essence, track, and, trace infrastructure transforms serialization from a compliance requirement into a strategic tool for supply chain transparency, disruption management, and global product security.
Looking ahead, the integration of digital manufacturing systems, serialization infrastructure, and advanced analytics is creating a more connected pharmaceutical ecosystem. How do you see this convergence influencing the way pharmaceutical companies approach operational transparency, regulatory oversight, and ultimately patient safety?
The convergence of digital manufacturing systems, serialization infrastructure, and advanced analytics is moving pharmaceutical operations toward a fully connected and transparent ecosystem.
First, this integration enables end, to, end operational visibility, from raw material processing and batch production to serialized product distribution. When manufacturing data and supply chain events are connected, companies gain a continuous digital record of product lifecycle activity, significantly improving operational transparency.
Second, for regulators, this level of connectivity strengthens data traceability and audit readiness. Instead of reviewing fragmented records, regulators can rely on digitally verifiable data trails that link manufacturing execution, quality events, and product movement across the supply chain.
Finally, this convergence has a direct impact on patient safety. With integrated systems and analytics, pharmaceutical companies can detect anomalies earlier, respond faster to quality issues, and trace affected products with precision if recalls are required.
Ultimately, the industry is moving toward a data, driven pharmaceutical ecosystem, where connected manufacturing, supply chain intelligence, and regulatory visibility collectively ensure higher operational reliability, stronger compliance, and greater protection for patients.
Disclaimer: The views and opinions expressed in this editorial are those of the interviewees and are based on their professional experience in pharmaceutical engineering and sterile manufacturing. They do not necessarily reflect the official views, policies, or positions of Hello Pharma, its management, or its affiliates. Hello Pharma does not endorse or take responsibility for any specific technical, commercial, or regulatory interpretations presented in this article. Readers are encouraged to independently evaluate the information shared, review applicable regulatory guidance, and rely on their own experience, expertise, and professional judgment before making decisions related to equipment selection, system design, validation strategy, or regulatory compliance.
